share_log

6-K: Us Fda Accepts for Priority Review Gsk's Application for an Expanded Indication of Jemperli Plus Chemotherapy to Include All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer

6-K: Us Fda Accepts for Priority Review Gsk's Application for an Expanded Indication of Jemperli Plus Chemotherapy to Include All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer

GSK PLC:美國FDA接受優先審查葛蘭素史克擴大Jemperli Plu化療適應症的申請,以涵蓋所有原發性晚期或複發性子宮內膜癌成年患者
美股sec公告 ·  04/24 06:48
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息